- World Pharma News Home » Product » Rasilez®* reduces left ventricular hypertrophy, a powerful predictor of heart disease
(a free service delivered by FeedBurner)
Rasilez® (aliskiren), the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy, a proven predictor of heart disease, that are comparable to those seen with the current standard-of-care treatment[1]. Left ventricular hypertrophy (LVH), or abnormal thickening of the heart muscle, often results from high blood pressure[2]. Affecting nearly a third of patients with high blood pressure, LVH decreases the heart's ability to work efficiently and more than doubles a patient's risk of premature cardiovascular events or death[6].
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments